Application of Translational Science to Clinical Development - Genomic Biomarkers for Pharmaceutical Development - page 20

[42] Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signa-
tures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
[43] Niewold TB, Rivera TL, Buyon JP, Crow. MK. Serum type I interferon activity is dependent on maternal diag-
nosis in anti-SSA / Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008;58:541-6.
[44] Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible
gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA
2003;100:2610-15.
[45] Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha / beta-mediated
innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
[46] Farina G, Lafyatis D, Lemaire R, Lafyatis. R. A four-gene biomarker predicts skin disease in patients with dif-
fuse cutaneous systemic sclerosis. Arthritis Rheum 2010;62:580-8.
[47] Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus:
points in an interferon-mediated continuum. Arthritis Rheum 2010;62:589-98.
[48] Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad. AI. Gene expression proiling of minor salivary
glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis
Rheum 2005;52:1534-44.
[49] Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus,
myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann
Rheum Dis 2011;70:2029-36.
[50] Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus
plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
[51] Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr
Opin Immunol 2006;18:676-82.
[52] Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-
alpha / beta-inducible genes and downstream effect in a Phase I trial of an anti-interferon-alpha monoclonal
antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
[53] Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakeield XO. Codon-optimized Gaussia luciferase
cDNA for mammalian gene expression in culture and in vivo . Mol Ther 2005;11:435-43.
[54] Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr. JC. Type I interferon correlates with serological and
clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7.
[55] Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of inter-
feron-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
[56] Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P, et al. Development of potential phar-
macodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythe-
matosus. Hum Genomics Proteomics 2009 , http://dx.doi.org/pii:374312.
[57] Coelho LF, de Oliveira JG, Kroon EG. Interferons and scleroderma—a new clue to understanding the patho-
genesis of scleroderma? Immunol Lett 2008;118:110-15.
[58] Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system
activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396-402.
[59] Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-
regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436-46.
[60] Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the
peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59-68.
[61] Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. Sifalimumab, an anti-IFN-α mAb,
shows target suppression of a type I IFN signature in blood and muscle of dermatomyositis and polymyositis
patients. Ann Rheum Dis 2013;February 23 , http://dx.doi.org/10.1136/annrheumdis-2012-202794.
[62] Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety proile and clinical activity of sifali-
mumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a Phase I,
multicenter, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
[63] Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, et al. Pharmacogenomics and translational simu-
lations to bridge indications for an anti-interferon-α receptor antibody. Clin Pharmacol Ther 2013;February 14.
http://dx.doi.org/:10.1038 / clpt.2013.35.J.
[64] DiMasi A, Grabowski. HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
[65] DiMasi JA, Feldman L, Seckler A, Wilson. A. Trends in risks associated with new drug development: success
rates for investigational drugs. Clin Pharmacol Ther 2010;87:272-7.